In some embodiments, the otic formulation or composition comprises about 0.6% by weight of the therapeutic agent, or pharmaceutically acceptable prodrug or salt thereof
As phase III trial data for retatrutide emerge and regulatory submissions are made, it is anticipated that formal guidance will be developed
Both short-acting (e.g., insulin aspart, insulin lispro) and long-acting insulins (e.g., insulin detemir, insulin glargine) are considered safe
Because GLP-1 medications can occasionally affect hydration and kidney markers, it is vital to have your lab work monitored by a clinical team
Physical symptoms like muscle weakness or tingling in extremities (if present) may start to improve
However, sharp or persistent pain may mean the injection technique or site needs adjusting